Company Insights

UTHR customer relationships

Explore interactive graphBrowse insights index
UTHR customer relationship map

United Therapeutics (UTHR) — Customer Relationships That Drive Revenue and Risk

United Therapeutics sells specialty pharmaceuticals and medical devices primarily by executing distribution agreements with a small set of specialty distributors and a handful of international partners. The company recognizes revenue on transfer of control to distributors, and treprostinil-based therapies (Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram) account for the majority of sales, concentrated through contracted partners in the United States and exclusive partners overseas. This concentration creates a predictable channel for monetization but also a single-point distribution risk for investors assessing counterparty exposure. For more structured relationship intelligence, visit https://nullexposure.com/.

Why distributors determine UTHR's commercial profile

United Therapeutics operates as a specialty drug manufacturer that relies on distribution partnerships rather than direct-to-patient logistics. The company sells finished product into the wholesale/specialty pharmacy channel, earning the bulk of treprostinil-related revenue when product ships to distributors. United Therapeutics has structured a mix of non‑exclusive U.S. distribution agreements with two large specialty distributors and exclusive arrangements for select products and territories, which influences negotiation leverage, revenue concentration, and operational contingency planning.

  • Concentration: UTHR derives substantially all treprostinil-based revenues from two U.S. distributors, creating material revenue dependence on those partners (see constraints below).
  • Contracting posture: Contracts are a mix of non‑exclusive U.S. distribution agreements and exclusive territory/product agreements overseas, supporting scale while protecting selected assets.
  • Criticality and maturity: Treprostinil therapies are core commercial products and revenue drivers; distribution relationships are active and commercial-stage, not development-stage collaborations.

If you want a compact view of counterparty footprints and contractual posture, explore our portal at https://nullexposure.com/.

Operational constraints that shape risk and opportunity

Company-level signals from filings indicate the following operating model characteristics for United Therapeutics:

  • Materiality and criticality: Treprostinil-based therapies produced 56% of total revenues in 2024, confirming that distribution relationships for those products are material and critical to cash flow generation (United Therapeutics 2024 Form 10‑K).
  • Geographic concentration: U.S. distribution is the core revenue channel for treprostinil products; international revenue flows through named exclusive partners in several markets (10‑K disclosures).
  • Contract types and stage: The firm uses non‑exclusive distribution agreements in the U.S. (Accredo and CVS Specialty) and exclusive distribution agreements for specific products/territories (Cencora for Unituxin and other named partners overseas). Filings show these relationships are active with ongoing commercial shipments since 2022 for Tyvaso DPI.
  • Role and segmentation: United Therapeutics is the seller/manufacturer; counterparties function primarily as distributors in the distribution segment, with services revenue recognized separately in ex vivo lung perfusion and selected overseas arrangements.

This structure supports stable wholesale revenue recognition but creates dependency on a compact set of distribution partners.

Relationship catalogue: line-by-line (each entry from filings and reporting)

  • Accredo Health Group — United Therapeutics named Accredo among specialty pharmacies involved in litigation referenced in its 2024 Form 10‑K, indicating Accredo’s role as a counterpart in distribution or downstream disputes. According to the 2024 10‑K, Accredo is one of the specialty pharmacy entities named in related litigation (10‑K, FY2024).
  • CuraScript SD Specialty Distribution (Priority Healthcare Distribution, Inc.) — UTHR references a Wholesale Product Purchase Agreement with Priority Healthcare (d/b/a CuraScript SD), reflecting an active wholesale distribution contract incorporated by reference in its filings (10‑K, FY2024).
  • CVS Health Corporation — CVS is identified with other specialty pharmacies in a second amended complaint cited in the company’s 2024 10‑K, signaling CVS’s involvement in the specialty pharmacy channel that handles UTHR products (10‑K, FY2024).
  • Express Scripts Holding Company — Express Scripts Holding Company is named alongside other specialty pharmacies in the 2024 10‑K’s litigation discussion, showing its historical role in the specialty pharmacy/distribution landscape for UTHR products (10‑K, FY2024).
  • Express Scripts, Inc. — Express Scripts, Inc. appears separately in the same litigation narrative from the 2024 10‑K and therefore is recorded as a named specialty pharmacy counterparty (10‑K, FY2024).
  • CVS Specialty (Caremark, L.L.C.) — United Therapeutics states it distributes core products through two contracted specialty distributors: Accredo and Caremark/ CVS Specialty, which supply the U.S. channel for Tyvaso DPI, nebulized Tyvaso, Remodulin, Remunity pumps, and Orenitram (StockTitan summary of UTHR 10‑K, reported March 2026; FY2026 disclosure).
  • Accredo — The company reiterates that Accredo is a contracted specialty distributor responsible for a substantial portion of U.S. treprostinil revenues, through non‑exclusive distribution agreements (StockTitan summary of 10‑K disclosures, March 2026; FY2026).
  • Cencora Global Procurement Ltd. — UTHR has an exclusive distribution agreement with Cencora Global Procurement Ltd. to distribute Unituxin in the United States, establishing a single‑partner channel for that specific product (StockTitan summary of 10‑K, March 2026; FY2026).
  • Accredo Health Group, Inc. (Accredo) — The company cites a Specialty Pharmacy Network Agreement dated January 1, 2018 between United Therapeutics and Accredo Health Group, Inc., confirming a formal ongoing contractual relationship (StockTitan/10‑K exhibits, FY2026).
  • Caremark, L.L.C. (CVS Specialty) — The 10‑K incorporates language that Caremark, L.L.C. acts as CVS Specialty and is a contracted distributor for U.S. treprostinil products (StockTitan / 10‑K reporting, FY2026).
  • Cencora Global Procurement Ltd (Cencora) — The filings repeat that Unituxin is distributed in the U.S. via an exclusive agreement with Cencora, clarifying exclusive channel rights for that asset (StockTitan / 10‑K, FY2026).
  • Priority Healthcare Distribution, Inc. (d/b/a CuraScript SD Specialty Distribution) — A wholesale purchase agreement dated January 1, 2018 with Priority Healthcare d/b/a CuraScript SD is incorporated by reference as an exhibit in UTHR filings, evidencing a long‑standing distribution contract (StockTitan / 10‑K exhibits, FY2026).
  • Grupo Ferrer Internacional, S.A. (Ferrer) — Ferrer is identified as United Therapeutics’ primary distributor outside the United States for Remodulin and holds marketing authorization rights in several territories (StockTitan/10‑K, FY2026).
  • Mochida Pharmaceutical Co., Ltd. (Mochida) — United Therapeutics sells Nebulized Tyvaso in Japan exclusively through Mochida, where approvals for PAH and PH‑ILD were obtained, indicating an exclusive country-level commercial partner (StockTitan/10‑K, FY2026).
  • Ohara Pharmaceutical Co., Ltd. — Ohara is the exclusive distributor for Unituxin in Japan following marketing authorization in mid‑2021, making Ohara the on-the-ground commercial partner for that product in Japan (StockTitan/10‑K, FY2026).
  • Accredo Health Group, Inc. — The filings list Accredo Health Group, Inc. again in the exhibit schedule as a contract counterparty, reinforcing Accredo’s central role across multiple agreements (10‑K exhibits, FY2026).
  • Lilly (Eli Lilly and Company) — United Therapeutics holds an exclusive U.S. license from Lilly to develop, market, and commercialize Adcirca, establishing a historic license relationship that enabled UTHR’s U.S. commercialization of that product (10‑K, FY2024).

What investors should watch next

  • Counterparty concentration: Two U.S. distributors (Accredo and CVS Specialty) drive the treprostinil revenue stream; any contract disputes, reimbursement shifts, or operational failures at those partners will have outsized impact on UTHR top-line.
  • Exclusive partner single points: Exclusive arrangements (Cencora for Unituxin; Mochida and Ohara in Japan) create high-revenue but single-partner dependencies that require monitoring for renewal terms and distribution performance.
  • Regulatory and litigation exposure: Named specialty pharmacies appear in litigation disclosures; track filings for resolution and potential commercial implications.

For targeted counterparty mapping and alerts on these partners, visit https://nullexposure.com/ to see how relationship intelligence can shape investment and operational decisions.

United Therapeutics’ business model is highly commercial and distribution‑dependent. Investors should weigh the predictability of wholesale revenue recognition against the concentration and exclusivity risks inherent in the current partner footprint. For an executive summary and tailored monitoring of these relationships, go to https://nullexposure.com/.